# Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat Canonical URL: https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat Ticker: TNGX Company: Tango Therapeutics Source: Tango Therapeutics Published: 2026-04-15 13:05 EST Original Source URL: https://ir.tangotx.com ## Summary -  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed ## Article Body - Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed ## Recent Company News - 2026-05-13 20:08 EST — [Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights) — Source: Tango Therapeutics - 2026-05-04 20:31 EST — [Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Tango Therapeutics - 2026-04-15 13:05 EST — [Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat) — Source: Tango Therapeutics - 2026-03-05 12:00 EST — [Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights) — Source: Tango Therapeutics - 2026-02-18 12:00 EST — [Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences](https://biopharmsignal.com/news/TNGX/tango-therapeutics-to-report-fourth-quarter-2025-financial-results-and-participate-in-three-upcoming-investor-conferences) — Source: Tango Therapeutics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)